SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

News in brief

Catalent and Cevec team-up to offer protein CDMO services

15-Nov-2012
Last updated on 15-Nov-2012 at 11:58 GMT

Catalent and Cevec's new protein CDMO services

Catalent and Cevec Pharmaceuticals have joined forces to offer cell line development and manufacturing services to biotechs.

The alliance will combine Catalent’s GPEx gene-insertion tech with Cevec’s CAP cell line protein expression platform, derived from primary human aminocytes.

The deal follows a joint-study for complex protein production, which saw “record” yields of non-antibody proteins produced in a human expression system.

In a joint statement, the firms said they “achieved a manufacturing yield of over three grams per ltr for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative  proprietary technologies.”

Kent Payne, VP and general manager of Catalent’s biologics business said: “We look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products